Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program.
The speakers and agenda are as follows:
Introduction
Vincent M. Brandenburg, MD - University Hospital of the RWTH Aachen, Germany
Cardiovascular disease in diabetes and CKD & residual risk - The promise of epigenetics
Erik Stroes, MD - Academic Medical Centre,
Amsterdam, The Netherlands
Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD
Louise Nordfors, PhD - Karolinska Institute, Stockholm, Sweden
A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives
Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA
The symposium presentations will be made available at: http://pace-cme.org/bet-inhibition/ shortly after the live event.
Lesen Sie auch
"The presentations at the ERA-EDTA Congress highlight the opportunity and need for a novel approach to reduce risk in kidney and cardiovascular disease, and demonstrate the important role for epigenetics in the underlying pathology of these diseases," commented Donald J. McCaffrey, President and CEO. "Based on its mechanism as recently published by Kulikowski et al. Kidney & Blood Pressure Research, 2018, BET-inhibition by apabetalone has the potential to address the significant unmet medical need in kidney disease patients both with regard to kidney function and the accentuated cardiovascular risk," Mr. McCaffrey continued.